Clinical trials: Radioligand
Dementia
PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel Translocator Protein (TSPO) Radioligand
Background: Aging-related progressive neurological disorders include frontotemporal dementia, Lou Gehrig s disease, and Alzheimer s disease. Little is known about what causes these disorders. Brain inflammation may be involved.
- Trial name
- NCT03958630
- Testing
- 11C-ER176, 11C-PIB, Positron Emission Tomography (PET) Scan
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
COVID Long-Haul
Long COVID-19 [11C]CPPC Study
The goal of this study is to evaluate the safety of using the [5-cyano-N-(4-(4-[11C]Methylpiperazin-1-yl)-2-(Piperidin-1-yl)Phenyl)Furan-2-carboxamide] ([11C]CPPC) radiotracer in positron emission tomography (PET) imaging of…
- Trial name
- NCT06223971
- Testing
- [11C]CPPC Injection
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Prostate Cancer (Adenocarcinoma), Prostate Biopsy
RegisterPROS - A Registry for Prostate Cancers
Prostate cancers are derived from epithelial cells in the prostate gland. Treatment options include surgery, medical (androgen signaling targeted and chemotherapy) and radiation therapy including radioligand therapy (RLT).
- Conditions
- Prostate Cancer (Adenocarcinoma), Prostate Biopsy, Prostatectomy, Radioligand
- Trial name
- RegisterPROS (NCT06872619)
- Testing
- PROSTest
- Where
- Germany
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Wren Laboratories LLC
Pharmacokinetics, Adult
Evaluation of a Novel PET Radioligand to Image OGA
Background: O-GlcNAcase (OGA) is a brain enzyme. It may play a role in brain disorders like Alzheimer s disease. Researchers want to see if a new drug can be used with positron emission tomography (PET) scans to show OGA better.
- Trial name
- NCT03632226
- Testing
- 18F-OGA-1
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Drug Resistance
(18F)FCWAY and the Blood-Brain Barrier
Background: The blood-brain barrier helps protect the brain from infections and toxins in the blood stream. But it can also prevent certain drugs from reaching the brain to treat diseases or other problems.
- Trial name
- NCT01386476
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Huntington Disease
iMagemHTT: FIH Evaluation of Novel Mutant Huntingtin PET Radioligands [¹¹C]CHDI-00485180-R and [¹¹C]CHDI-00485626
This is a FIH (first-in-human) adaptive PET (Positron Emission Tomography) imaging study to explore the binding and kinetic properties of two potential mutant huntingtin (mHTT) radioligands; [¹¹C]CHDI-00485180-R and…
- Trial name
- NCT03810898
- Testing
- Radioligand [¹¹C]CHDI-00485180-R, Radioligand [¹¹C]CHDI-00485626
- Where
- Belgium
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- CHDI Foundation, Inc.
Alzheimer's Disease (AD), Progressive Supranuclear Palsy (PSP)
Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies
The overall goal of this imaging trial is to characterize [18F]MNI-815, a PET radioligand for imaging Tau.
- Conditions
- Alzheimer's Disease (AD), Progressive Supranuclear Palsy (PSP), Cortical Basal Syndrome (CBS), Frontal Temporal Dementia (FTD)
- Trial name
- NCT02531360
- Testing
- [18F]MNI-815 (MNI-815)
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Molecular NeuroImaging
Healthy Volunteer, Alzheimer Disease
Evaluation of [18F]PI-2620 as a Potential Positron Emission Computed Tomography Radioligand for Imaging Tau Protein in the Brain
The overall goal of this imaging trial is to evaluate [18F]PI-2620, a tau targeted positron emission computed tomography radioligand, in individuals with tauopathies and healthy volunteers (HV).
- Conditions
- Healthy Volunteer, Alzheimer Disease, Frontotemporal Dementia, Parkinson Disease
- Trial name
- NCT03510572
- Testing
- [18F]PI-2620
- Where
- South Korea
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Asan Medical Center
Depression
Title: Evaluation of a Novel PET Radioligand for Phosphodiesterase-4D (PDE4D)
Background: The brain enzyme phosphodiesterase-4D (PDE4D) may affect thinking and depression. Drugs with some radioactivity can attach to enzymes and be seen on a scan.
- Trial name
- NCT03861000
- Testing
- [C-11]T-1650, BPN14770
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Depression
A Study of Nociceptin/Orphanin FQ Peptide Receptor Occupancy in Healthy Subjects
The purpose of this trial is to conduct an assessment of brain nociceptin/orphanin FQ peptide (NOP) receptor occupancy (RO) in healthy subjects.
- Trial name
- NCT01404091
- Testing
- LY2940094
- Where
- Canada
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- BlackThorn Therapeutics, Inc.
Baseline, Blocking Receptor Binding
Specific PET Radioligand Binding to Translocator Protein
Background: A brain protein called translocator protein (TSPO) shows changes in some brain diseases. A radioactive drug called 11C-(R)-PK 11195 is used to take pictures of TSPO using a camera called positron emission tomography…
- Trial name
- NCT02181582
- Testing
- Emapunil, PET
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
ALS
Study of [11C]CPPC as a Clinical PET Radioligand Biomarker of Microglial Activation in ALS
1. Establish the safety and tolerability of the 5-cyano-N-(4-(4-[11C]Methylpiperazin-1-yl)-2-(Piperidin-1-yl)Phenyl)Furan-2-carboxamide ([11C]CPPC) PET radioligand in ALS patients and controls 2.
- Trial name
- NCT05602142
- Testing
- [11C]CPPC PET ligand
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Huntington Disease, HD
iMagemHTT-009- FIH Evaluation of Novel Mutant Huntingtin PET Radioligand [11C]CHDI-00491009
This is a FIH (first-in-human) study to evaluate the clinical utility of the radioligand [11C]CHDI-00491009 as a PET tracer that binds specifically to mutant huntingtin (mHTT) aggregates in Huntington's disease (HD).
- Conditions
- Huntington Disease, HD, PET Tracer, Positron Emission Tomography
- Trial name
- iMagemHTT-009 (NCT06634628)
- Testing
- Radioligand [11C]CHDI-00491009
- Where
- Belgium
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- CHDI Foundation, Inc.
Alpha-Synucleinopathy, Parkinson's Disease
Study to Evaluate a Potential PET Radioligand for Imaging Alpha-synuclein Deposits in the Brain
The overall goal of this protocol is to evaluate [18F]MNI-1216 (also known as [18F]ACI-12589) as an α-synuclein targeted radiopharmaceutical in 3 parts as follows: Part 1: first in human (FiH) imaging Optional Part 2: expansion…
- Conditions
- Alpha-Synucleinopathy, Parkinson's Disease, Dementia With Lewy Bodies, Multisystem Atrophy
- Trial name
- NCT06445465
- Testing
- [18F]MNI-1216
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Invicro
Brain Distribution of [11C]AZ12807110 and AZD5213
Evaluation of Histamine H3 Receptor Radioligand [11C]AZ12807110 and Histamine H3 Receptor Occupancy of AZD5213 After Oral Administration
The purpose of this study is to investigate features of radioligand [11C]AZ12807110 and how much AZD5213 displaces radioligand from histamine receptors when given together.
- Trial name
- NCT01194986
- Testing
- [11C]AZ12807110, AZD5213
- Where
- Sweden
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Alzheimer's Disease
Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
This is an open-label, longitudinal observational study evaluating the imaging characteristics of the tau positron-emission tomography (PET) radioligand [18F] Genentech Tau Probe 1 (GTP1) in the brain of participants with…
- Trial name
- NCT02640092
- Testing
- [18F]GTP1
- Where
- 16 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Healthy
A Study of the Effects of LY3372689 on the Brain in Healthy Participants
This study uses imaging to evaluate how LY3372689 binds to a protein in the brain. This study will be conducted in healthy participants and will last up to approximately 25 days after enrollment.
- Trial name
- NCT03944031
- Testing
- LY3372689, [18F]LSN3316612
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Progressive Supranuclear Palsy
Test-retest Study With [18F]PI-2620 in PSP-RS and NDC
The overall goal of this protocol is to evaluate the imaging characteristics of [18F]PI-2620 using positron emission tomography (PET) in patients with progressive supranuclear palsy, Richardson's syndrome (PSP-RS)
- Trial name
- NCT05187546
- Testing
- [18F]-PI2620
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Life Molecular Imaging GmbH
Alcohol Dependence
A Study of Brain Receptor Occupancy in Healthy Subjects
To measure the occupancy of brain kappa opioid receptors after single oral doses of LY2456302.
- Trial name
- NCT01232439
- Testing
- opioid receptor kappa antagonist
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
[11C]Cimbi-36 Dosimetry
The purpose of this study is to determine the dosimetry for the Positron Emission Tomography (PET) tracer [11C]Cimbi-36 in two different Carbon-11 labelling positions.
- Trial name
- NCT02629003
- Testing
- [11C]Cimbi-36, [11C]Cimbi-36-5
- Where
- Denmark
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Gitte Moos Knudsen